Valuation : PolyPid Ltd.

Market Cap 109M 94.21M 88.64M 80.97M 151M 10.34B 152M 1.05B 406M 5.3B 411M 402M 17.09B P/E 2026 *
-6.06x
P/E 2027 * -4.39x
Enterprise Value 109M 94.21M 88.64M 80.97M 151M 10.34B 152M 1.05B 406M 5.3B 411M 402M 17.09B EV / Sales 2026 *
7.3x
EV / Sales 2027 * 12.6x
Free-Float
82.21%
Yield 2026 *
-
Yield 2027 * -
1 day+2.28%
1 week+6.31%
Current month+4.86%
1 month+21.12%
3 months+11.59%
6 months+26.82%
Current year+24.19%
1 week 5
Extreme 5
5.55
1 month 4.45
Extreme 4.45
5.55
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
9.3
5 years 2.3
Extreme 2.3
257.1
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 30/06/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 17/08/2025
Director TitleAgeSince
Director/Board Member 84 31/03/2008
Director/Board Member 52 07/08/2022
Director/Board Member 74 30/11/2018
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Free

Director

9,132 0.0896%
15/07/26 Free

Director

9,132 0.0896%
15/07/26 Free

Chairman

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+2.28%+6.31%+58.53%-40.11% 109M
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -0.66%+1.61%+31.32%+42.01% 367.85B
Weighted average by Cap. -1.10%+0.55%+36.62%+66.22%

Financials

2026 *2027 *
Net sales 15M 12.91M 12.14M 11.09M 20.75M 1.42B 20.81M 144M 55.69M 727M 56.33M 55.1M 2.34B 8.68M 7.46M 7.02M 6.42M 12M 819M 12.03M 82.99M 32.21M 420M 32.58M 31.87M 1.35B
Net income -20.03M -17.23M -16.21M -14.81M -27.71M -1.89B -27.78M -192M -74.34M -970M -75.2M -73.56M -3.13B -31.55M -27.15M -25.54M -23.33M -43.65M -2.98B -43.77M -302M -117M -1.53B -118M -116M -4.92B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
04/09/26 US$5.390 +2.28% 73,097
03/09/26 US$5.270 -0.57% 65,917
02/09/26 US$5.300 -0.56% 143,786
01/09/26 US$5.330 +3.70% 242,056
31/08/26 US$5.140 +1.38% 56,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.390USD
Average target price
11.75USD
Spread / Average Target
+118.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock